Tacalyx is focused on developing innovative anticancer therapeutics that specifically target Tumor Associated Carbohydrate Antigens (TACAs). These unique antigens are typically expressed during embryonic development but are largely absent in normal differentiated tissues. However, they are found at significantly elevated levels on tumor cells, making them promising targets for immunotherapeutic strategies. By leveraging the high expression of TACAs in cancer, Tacalyx aims to enhance the delivery of therapeutic agents directly to cancer cells, thereby improving treatment efficacy.

The company's pipeline includes several first-in-class therapeutic assets designed to target various TACAs across multiple solid tumors. These assets are versatile and can be utilized in different treatment modalities, such as antibody-drug conjugates and T cell engagers. Tacalyx's approach is underscored by a commitment to harnessing unique sugar patterns found on cancer cells, which is exemplified by their development of ultra-small antibodies, or nanobodies, derived from alpacas. This innovative technology positions Tacalyx at the forefront of antibody drug development, with the potential to significantly impact cancer treatment outcomes.

Germany

Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need

Tacalyx

Company Details